意大利任务：采访费德里科·明戈齐

The Italian Job: An Interview with Federico Mingozzi.

机构信息

Executive Editor, Human Gene Therapy.

出版信息

Hum Gene Ther. 2020 Oct;31(19-20):1027-1030. doi: 10.1089/hum.2020.29136.int.

DOI:10.1089/hum.2020.29136.int

Abstract

After a distinguished career in academic medicine, including stints at the Children's Hospital of Philadelphia, INSERM and Genethon, Federico Mingozzi joined Spark Therapeutics 3 years ago as chief scientific officer. Mingozzi aims to build on the company's landmark success with Luxturna, the approved therapy for certain retinal diseases such as the type 2 version of Leber's congenital amaurosis. In this exclusive interview with Executive Editor Kevin Davies, Mingozzi discusses his career highlights and surveys the hopes and challenges facing the human gene therapy community.

摘要

在学术医学领域有着杰出的职业生涯后，Federico Mingozzi 曾在费城儿童医院、法国国家健康与医学研究院和 Genethon 任职，3 年前加入 Spark Therapeutics 担任首席科学官。Mingozzi 的目标是在该公司治疗某些视网膜疾病（如 2 型 Leber 先天性黑矇）的 Luxturna 获批疗法的基础上更进一步。在这次与执行编辑 Kevin Davies 的独家访谈中，Mingozzi 讨论了他职业生涯中的亮点，并审视了人类基因治疗领域的希望和挑战。